Literature DB >> 6861865

Pharmacokinetics in man of a new antiarrhythmic drug, cibenzoline.

M Canal, B Flouvat, D Tremblay, A Dufour.   

Abstract

The kinetics of cibenzoline (UP 339.01), a new antiarrhythmic drug, was studied after i.v. and oral administration to 5 healthy subjects. Cibenzoline levels in plasma and urine cibenzoline were measured by a GLC method. After i.v. administration, the total clearance was 826 ml . min-1. The fraction of cibenzoline excreted unchanged in the urine was 0.602 and it was correlated with the creatinine clearance. After i.v. and oral administration, the renal clearances were 499 ml . min-1 and 439 ml . min-1, and the half-lives were 4 h 01 min and 3 h 24 min, respectively. The differences were not significant. Availability by the oral route was 0.92, the maximum plasma concentration being observed at 1 h 36 min. The results were compared with those for other antiarrhythmic drugs.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6861865     DOI: 10.1007/bf00609894

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  17 in total

1.  Metabolism of procainamide in normal and cardiac subjects.

Authors:  E G Giardina; J Dreyfuss; J T Bigger; J M Shaw; E C Schreiber
Journal:  Clin Pharmacol Ther       Date:  1976-03       Impact factor: 6.875

2.  Pharmacokinetics of the antiarrhythmic disopyramide in healthy humans.

Authors:  P H Hinderling; E R Garrett
Journal:  J Pharmacokinet Biopharm       Date:  1976-06

3.  Influence of renal failure on disopyramide pharmacokinetics [proceedings].

Authors:  J A Henry; A Johnston; S J Warrington; N A Hamer
Journal:  Br J Clin Pharmacol       Date:  1979-04       Impact factor: 4.335

4.  Pharmacokinetics of procainamide.

Authors:  H S Weily; E Genton
Journal:  Arch Intern Med       Date:  1972-09

5.  Influence of route of administration on drug availability.

Authors:  M Rowland
Journal:  J Pharm Sci       Date:  1972-01       Impact factor: 3.534

6.  Procainamide dosage schedules, plasma concentrations, and clinical effects.

Authors:  J Koch-Weser; S W Klein
Journal:  JAMA       Date:  1971-03-01       Impact factor: 56.272

7.  Elimination of procainamide in end stage renal failure.

Authors:  T P Gibson; D T Lowenthal; H A Nelson; W A Briggs
Journal:  Clin Pharmacol Ther       Date:  1975-03       Impact factor: 6.875

8.  Effects on rabbit nodal, atrial, ventricular and Purkinje cell potentials of a new antiarrhythmic drug, cibenzoline, which protects against action potential shortening in hypoxia.

Authors:  J S Millar; E M Vaughan Williams
Journal:  Br J Pharmacol       Date:  1982-03       Impact factor: 8.739

9.  Pharmacokinetics of oral disopyramide phosphate in patients with renal impairment.

Authors:  A Johnston; J A Henry; S J Warrington; N A Hamer
Journal:  Br J Clin Pharmacol       Date:  1980-09       Impact factor: 4.335

10.  Kinetics and bioavailability of mexiletine in healthy subjects.

Authors:  V Häselbarth; J E Doevendans; M Wolf
Journal:  Clin Pharmacol Ther       Date:  1981-06       Impact factor: 6.875

View more
  11 in total

Review 1.  Pharmacokinetics of newer drugs in patients with renal impairment (Part II).

Authors:  E Singlas; J P Fillastre
Journal:  Clin Pharmacokinet       Date:  1991-05       Impact factor: 6.447

Review 2.  Adverse effects of class I antiarrhythmic drugs.

Authors:  J Caron; C Libersa
Journal:  Drug Saf       Date:  1997-07       Impact factor: 5.606

Review 3.  Clinical pharmacokinetics of drugs in patients with heart failure: an update (part 2, drugs administered orally).

Authors:  Ryuichi Ogawa; Joan M Stachnik; Hirotoshi Echizen
Journal:  Clin Pharmacokinet       Date:  2014-12       Impact factor: 6.447

4.  Pharmacokinetics of oral cibenzoline in arrhythmia patients.

Authors:  R K Brazzell; W A Colburn; K Aogaichi; A J Szuna; J C Somberg; N Carliner; J Heger; J Morganroth; R A Winkle; P Block
Journal:  Clin Pharmacokinet       Date:  1985 Mar-Apr       Impact factor: 6.447

5.  Effect of food on cibenzoline bioavailability.

Authors:  J W Massarella; H P Blumenthal; T Silvestri; A Lin
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

6.  Cibenzoline inhibits diazoxide- and 2,4-dinitrophenol-activated ATP-sensitive K+ channels in guinea-pig ventricular cells.

Authors:  T Sato; B Wu; S Nakamura; T Kiyosue; M Arita
Journal:  Br J Pharmacol       Date:  1993-02       Impact factor: 8.739

Review 7.  Cibenzoline. A review of its pharmacological properties and therapeutic potential in arrhythmias.

Authors:  D W Harron; R N Brogden; D Faulds; A Fitton
Journal:  Drugs       Date:  1992-05       Impact factor: 9.546

8.  Haemodynamic effects of intravenous cibenzoline in patients with coronary heart disease.

Authors:  M van den Brand; P Serruys; Y de Roon; M F Aymard; A Dufour
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

Review 9.  New antiarrhythmic drugs.

Authors:  P F Nestico; J Morganroth; L N Horowitz
Journal:  Drugs       Date:  1988-03       Impact factor: 9.546

10.  Inhibition of the myocardial Ca2+ inward current by the class 1 antiarrhythmic agent, cibenzoline.

Authors:  M Holck; W Osterrieder
Journal:  Br J Pharmacol       Date:  1986-04       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.